The Challenge of Overcoming Antibiotic Resistance: An Adjuvant Approach?

被引:177
作者
Melander, Roberta J. [1 ]
Melander, Christian [1 ]
机构
[1] North Carolina State Univ, Dept Chem, 2620 Yarbrough Dr, Raleigh, NC 27695 USA
来源
ACS INFECTIOUS DISEASES | 2017年 / 3卷 / 08期
基金
美国国家卫生研究院;
关键词
BETA-LACTAMASE INHIBITORS; STAPHYLOCOCCUS-AUREUS; COMBINATION THERAPY; EFFLUX PUMPS; BAD BUGS; STRATEGIES; DRUGS; POTENTIATION; INFECTIONS; MECHANISMS;
D O I
10.1021/acsinfecdis.7b00071
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Antibiotic resistance is one of the greatest current threats to human health, and without significant action we face the chilling prospect of a world without effective antibiotics. Although continued effort toward the development of new antibiotics, particularly those with novel mechanisms of action, remains crucial, this alone probably will not be enough to prevail, and it is imperative that additional approaches are also explored. One such approach is the identification of adjuvants that augment the activity of current antibiotics. This approach has the potential to render an antibiotic against which bacteria have developed resistance once again effective, to broaden the spectrum of an antibiotic, and to lower the required dose of an antibiotic. In this viewpoint we discuss some of the advantages and disadvantages of the use of adjuvants, and describe various approaches to their identification.
引用
收藏
页码:559 / 563
页数:5
相关论文
共 53 条
  • [1] RecA Inhibitors Potentiate Antibiotic Activity and Block Evolution of Antibiotic Resistance
    Alam, Md Kausar
    Alhhazmi, Areej
    DeCoteau, John F.
    Luo, Yu
    Geyer, C. Ronald
    [J]. CELL CHEMICAL BIOLOGY, 2016, 23 (03): : 381 - 391
  • [2] Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa
    Alipour, Misagh
    Suntres, Zacharias E.
    Omri, Abdelwahab
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (02) : 317 - 325
  • [3] [Anonymous], 2014, Antimicrobial Resistance: Tackling a crisis forthe health and wealth of nations
  • [4] Antibiotics: the changing regulatory and pharmaceutical industry paradigm
    Bax, Richard
    Green, Samantha
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (05) : 1281 - 1284
  • [5] Molecular mechanisms of antibiotic resistance
    Blair, Jessica M. A.
    Webber, Mark A.
    Baylay, Alison J.
    Ogbolu, David O.
    Piddock, Laura J. V.
    [J]. NATURE REVIEWS MICROBIOLOGY, 2015, 13 (01) : 42 - 51
  • [6] Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
    Boucher, Helen W.
    Talbot, George H.
    Bradley, John S.
    Edwards, John E., Jr.
    Gilbert, David
    Rice, Louis B.
    Scheld, Michael
    Spellberg, Brad
    Bartlett, John
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) : 1 - 12
  • [7] Phosphorylation of BlaR1 in Manifestation of Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus and Its Abrogation by Small Molecules
    Boudreau, Marc A.
    Fishovitz, Jennifer
    Llarrull, Leticia I.
    Xiao, Qiaobin
    Mobashery, Shahriar
    [J]. ACS INFECTIOUS DISEASES, 2015, 1 (10): : 454 - 459
  • [8] The Quorum Sensing Inhibitor Hamamelitannin Increases Antibiotic Susceptibility of Staphylococcus aureus Biofilms by Affecting Peptidoglycan Biosynthesis and eDNA Release
    Brackman, Gilles
    Breyne, Koen
    De Rycke, Riet
    Vermote, Arno
    Van Nieuwerburgh, Filip
    Meyer, Evelyne
    Van Calenbergh, Serge
    Coenye, Tom
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [9] Antibacterial drug discovery in the resistance era
    Brown, Eric D.
    Wright, Gerard D.
    [J]. NATURE, 2016, 529 (7586) : 336 - 343